Chapter 4 - Immunotherapy in gastrointestinal cancers: Spotlight on the pivotal role of currently available biomarkers

Valentina Angerilli; Juan J. Andrade-Rojas; Matteo Fassan

doi:10.1016/B978-0-443-13376-3.00012-5

Chapter 4 - Immunotherapy in gastrointestinal cancers: Spotlight on the pivotal role of currently available biomarkers

Valentina Angerilli
, Juan J. Andrade-Rojas
, Matteo Fassan

Universidad de Cuenca

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Gastrointestinal (GI) cancers represent a major health burden, especially due to their elevated incidence and poor prognosis. In the past decade, immunotherapy, currently driven by the application of monoclonal antibodies targeting immune checkpoints, has revolutionized the therapeutic landscape of many solid tumors, including GI cancers. Unfortunately, only a subset of patients responds to immune checkpoint inhibitors, and the development of secondary resistance is increasing. In this chapter, we will outline the most relevant biomarkers for gastroesophageal, bowel, anal, and biliopancreatic cancers and gastroenteropancreatic neuroendocrine neoplasms, and we will discuss their prognostic and predictive value and their use in clinical practice.

Original language	English
Title of host publication	Principles of Immunotherapy Breast and Gastrointestinal Cancers
Editors	Michele Ghidini
Publisher	Elsevier, Academic Press
Chapter	4
Pages	83-102
ISBN (Print)	978-0-443-13376-3
DOIs	https://doi.org/10.1016/B978-0-443-13376-3.00012-5
State	Published - 2024

Publication series

Name	Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/B978-0-443-13376-3.00012-5

Cite this

Angerilli, V., Andrade-Rojas, J. J., & Fassan, M. (2024). Chapter 4 - Immunotherapy in gastrointestinal cancers: Spotlight on the pivotal role of currently available biomarkers. In M. Ghidini (Ed.), Principles of Immunotherapy Breast and Gastrointestinal Cancers (pp. 83-102). (Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy). Elsevier, Academic Press. https://doi.org/10.1016/B978-0-443-13376-3.00012-5

Angerilli, Valentina ; Andrade-Rojas, Juan J. ; Fassan, Matteo. / Chapter 4 - Immunotherapy in gastrointestinal cancers: Spotlight on the pivotal role of currently available biomarkers. Principles of Immunotherapy Breast and Gastrointestinal Cancers. editor / Michele Ghidini. Elsevier, Academic Press, 2024. pp. 83-102 (Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy).

@inbook{8a375ebd5c30445a95ca568c4ba13952,

title = "Chapter 4 - Immunotherapy in gastrointestinal cancers: Spotlight on the pivotal role of currently available biomarkers",

abstract = "Gastrointestinal (GI) cancers represent a major health burden, especially due to their elevated incidence and poor prognosis. In the past decade, immunotherapy, currently driven by the application of monoclonal antibodies targeting immune checkpoints, has revolutionized the therapeutic landscape of many solid tumors, including GI cancers. Unfortunately, only a subset of patients responds to immune checkpoint inhibitors, and the development of secondary resistance is increasing. In this chapter, we will outline the most relevant biomarkers for gastroesophageal, bowel, anal, and biliopancreatic cancers and gastroenteropancreatic neuroendocrine neoplasms, and we will discuss their prognostic and predictive value and their use in clinical practice.",

author = "Valentina Angerilli and Andrade-Rojas, \{Juan J.\} and Matteo Fassan",

year = "2024",

doi = "10.1016/B978-0-443-13376-3.00012-5",

language = "Ingl{\'e}s",

isbn = "978-0-443-13376-3",

series = "Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy",

publisher = "Elsevier, Academic Press",

pages = "83--102",

editor = "Michele Ghidini",

booktitle = "Principles of Immunotherapy Breast and Gastrointestinal Cancers",

}

Angerilli, V, Andrade-Rojas, JJ & Fassan, M 2024, Chapter 4 - Immunotherapy in gastrointestinal cancers: Spotlight on the pivotal role of currently available biomarkers. in M Ghidini (ed.), Principles of Immunotherapy Breast and Gastrointestinal Cancers. Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy, Elsevier, Academic Press, pp. 83-102. https://doi.org/10.1016/B978-0-443-13376-3.00012-5

Chapter 4 - Immunotherapy in gastrointestinal cancers: Spotlight on the pivotal role of currently available biomarkers. / Angerilli, Valentina; Andrade-Rojas, Juan J.; Fassan, Matteo.
Principles of Immunotherapy Breast and Gastrointestinal Cancers. ed. / Michele Ghidini. Elsevier, Academic Press, 2024. p. 83-102 (Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy).

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

TY - CHAP

T1 - Chapter 4 - Immunotherapy in gastrointestinal cancers: Spotlight on the pivotal role of currently available biomarkers

AU - Angerilli, Valentina

AU - Andrade-Rojas, Juan J.

AU - Fassan, Matteo

PY - 2024

Y1 - 2024

N2 - Gastrointestinal (GI) cancers represent a major health burden, especially due to their elevated incidence and poor prognosis. In the past decade, immunotherapy, currently driven by the application of monoclonal antibodies targeting immune checkpoints, has revolutionized the therapeutic landscape of many solid tumors, including GI cancers. Unfortunately, only a subset of patients responds to immune checkpoint inhibitors, and the development of secondary resistance is increasing. In this chapter, we will outline the most relevant biomarkers for gastroesophageal, bowel, anal, and biliopancreatic cancers and gastroenteropancreatic neuroendocrine neoplasms, and we will discuss their prognostic and predictive value and their use in clinical practice.

AB - Gastrointestinal (GI) cancers represent a major health burden, especially due to their elevated incidence and poor prognosis. In the past decade, immunotherapy, currently driven by the application of monoclonal antibodies targeting immune checkpoints, has revolutionized the therapeutic landscape of many solid tumors, including GI cancers. Unfortunately, only a subset of patients responds to immune checkpoint inhibitors, and the development of secondary resistance is increasing. In this chapter, we will outline the most relevant biomarkers for gastroesophageal, bowel, anal, and biliopancreatic cancers and gastroenteropancreatic neuroendocrine neoplasms, and we will discuss their prognostic and predictive value and their use in clinical practice.

UR - https://www.sciencedirect.com/science/chapter/edited-volume/abs/pii/B9780443133763000125?via%3Dihub

U2 - 10.1016/B978-0-443-13376-3.00012-5

DO - 10.1016/B978-0-443-13376-3.00012-5

M3 - Capítulo

SN - 978-0-443-13376-3

T3 - Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy

SP - 83

EP - 102

BT - Principles of Immunotherapy Breast and Gastrointestinal Cancers

A2 - Ghidini, Michele

PB - Elsevier, Academic Press

ER -

Angerilli V, Andrade-Rojas JJ, Fassan M. Chapter 4 - Immunotherapy in gastrointestinal cancers: Spotlight on the pivotal role of currently available biomarkers. In Ghidini M, editor, Principles of Immunotherapy Breast and Gastrointestinal Cancers. Elsevier, Academic Press. 2024. p. 83-102. (Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy). doi: 10.1016/B978-0-443-13376-3.00012-5

Chapter 4 - Immunotherapy in gastrointestinal cancers: Spotlight on the pivotal role of currently available biomarkers

Abstract

Publication series

UN SDGs

Access to Document

Other files and links

Cite this